FDA has announced the rates for prescription drug user fees for fiscal year 2018. The docket also contains rates for priority review vouchers, biosimilars, and outsourcing facilities. Application fees are assessed on certain types of applications and prescription drug program fees are assessed on certain approved products. When specific conditions are met, FDA may waive or reduce fees.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
